Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saphenous and IPACK block vs LIA in ACL reconstruction
NCT03680716Completed
- Sponsor
- Lausanne University Hospital
- Start
- Nov 2018
- Primary completion
- Oct 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of ropivacaine in postoperative pain, sponsored by Lausanne University Hospital. Primary endpoint: Total morphine consumption at 24 hours. Started Nov 2018; status: completed.
02
Drugs
ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03680716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03680716.